 SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores
SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores
Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores
Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores
IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores
Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores 
              The U.S.-India Business Council (USIBC) has concluded its Pharmaceutical & Biologics Executive Mission to Hyderabad and New Delhi, India. The delegation expressed its commitment to the Indian market; called for further dialogue with the government on issues related to pricing, intellectual property, and clinical trials; and explored partnership strategies for expanding greater access to healthcare and developing an innovation ecosystem in India. USIBC's Executive Mission was led by Justin McCarthy, Senior Vice President for Global Public Policy at Pfizer, and included senior representatives from Abbott, Actavis, Baxalta, Hospira, Johnson & Johnson, Merck, Mylan, and PhRMA.
On Monday April 20, the delegation met with top officials from both the Andhra Pradesh and Telangana Governments in Hyderabad. The delegation discussed investment opportunities in both states and identified the policy and regulatory conditions conducive to attracting investment in the life sciences sector. Although no investment commitments were made by the Council's member companies, USIBC and its membership remains committed to partnering at both the center and state levels to explore opportunities for growth.
In Delhi on April 21 and 22, the delegation met with the Ministry of Health, Ministry of Finance, Department of Industrial Policy and Promotion (DIPP), Department of Commerce, Department of Biotechnology, and the office of the Drugs Controller General of India. The delegation participated in an interactive roundtable discussion on Innovation & Intellectual Property Rights: A discussion on policies, practices, and opportunities for U.S.-India Business Relations organized jointly by USIBC and the Indian Institute of Corporate Affairs (IICA) and sponsored by Trilegal, a leading full service law firm in India. The delegation also joined briefings with U.S. Embassy officials.
"As an industry, we look forward to partnering with the Government of India at both the state and central levels," said Justin McCarthy, leader of the USIBC delegation. "We are encouraged by the positive signals we received on policy and regulatory issues that are critical to furthering growth of the industry, expanding healthcare access, and developing an innovation ecosystem in India."
Formed in 1975 at the request of the U.S. and Indian governments, the U.S.-India Business Council (USIBC) is the premier business advocacy organization advancing U.S.-India commercial ties. Today, USIBC is the largest bilateral trade association in the United States, with liaison presence in New York, Silicon Valley, and New Delhi, comprised of 300 of the top-tier U.S. and Indian companies. The Chairman of USIBC is Ajay Banga, CEO and President, MasterCard Worldwide.